ABT263 (Navitoclax) and the IPF-Treatment Drugs for a Healthier Aging
ISEF · 2017 Translational Medical Science Second Award
Overview
Cellular senescence, a permanent proliferative arrest of the cell cycle, is closely associated with aging. Clearing senescent cells may reduce vulnerability to disease and extend lifespan in humans. This project studied the effects of ABT263 (Navitoclax) and the current Idiopathic Pulmonary Fibrosis treatment drugs (Nintedanib and Pirfenidone) on the aging and apoptosis of senescent human fetal lung fibroblasts. In the first experiment, the cells were exposed to various combinations and concentrations of drugs and analyzed for relative concentrations of senescence markers (p16 and pRb) and apoptotic proteins (Cleaved PARP and cleaved caspase 9) by western blots. As ABT263’s concentration was increased, cellular cultures seemed to have higher apoptotic rates of the senescent fibroblasts and underwent a healthier aging (both determined by qualitative analysis of western blot images). In the second experiment, the results indicated by Cleaved PARP concentrations showed all 6 treatment types caused significantly different rates of apoptosis, since the F-Test statistic, 3.373, was higher than the critical value, 3.11, with a = 0.05. Similarly, according to Cleaved Caspase 9 concentrations, all 6 treatment types caused significantly different rates of apoptosis, since the F-Test statistic, 4.620, was higher than the critical value, 3.11, with a = 0.05. The cells receiving the “ABT263 and Nintedanib” treatment or “ABT263 only” treatment had the highest apoptotic rates of all the treatments and underwent the healthiest aging of all the cellular cultures. Keywords: Senescence, ABT263, Navitoclax, Aging, Nintedanib, Pirfenidone, age-related disease, IPF, Apoptosis, Cleaved Caspase 9, pRb, p16, Cleaved PARP
Awards (1)
- Second Award of $2,000 $2,000
Competition history
- ISEF 2017
Resources
Related projects
CSEF · 2013
Rapamycin Treatment Decreases the Secretion of Senescent Murine Cells with Wild-Type and Inactive p53
ISEF · 2024
Identification of Survivin as a Novel Longevity Biomarker: Towards Developing Novel Anti-Aging Therapeutics
ISEF · 2023
Effect of AGX-51 on Human Lung Fibroblasts
ISEF · 2024
The Secrets of Healthy Aging: Semi-Automated Discovery of Natural Senolytics
ISEF · 2024
Anti-Cancer Drug Resistance in Lung Cancer Can Be Attributed to Its Ability To Develop Senescence
CSEF · 2017
Efficacy of BIBR1532 in Combination with Nutrient Deprivation on Reduction of Cell Viability in MCF7 and HT1080
ISEF · 2015
DZ3: A Novel Analog that Selectively Targets and Eliminates Senescent Cells
AJAS · 2025
CDK9-Specific PROTAC 2 Treatment Sensitizes Pancreatic Cancer Cells to Navitoclax
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair